Collaborators

Clinical Tests

We offer OxPL-apoA and OxPL-apoB tests for clinical uses through Diazyme and Boston Heart Diagnostics.

Diazyme

Diazyme Laboratories’ assay uses a magnetic particle-based chemiluminescent immunoassay format — similar in principle to established chemiluminescent ELISA methods — where captured lipoproteins are detected with a specific labeled antibody that binds oxidized phospholipids, producing a light signal proportional to OxPL levels. The assay is fully automated, requires no manual sample pre-dilution, and provides reliable quantitative results that support assessment of oxidative stress and cardiovascular risk.

Intended for in vitro diagnostic use on automated chemistry systems, the DZ-Lite OxPL Lipoprotein Assay has broad applications in evaluating lipid-related disorders and contributes to enhanced cardiovascular disease risk profiling. Higher OxPL levels are linked to atherosclerosis and related cardiovascular conditions, making this assay a valuable tool for laboratories and clinicians focusing on comprehensive cardiovascular biomarker assessment.

See Diazyme sales sheet for more info.

Boston Heart Diagnostics

Boston Heart’s OxPL-apoB assay uses chemiluminescent immunoassay technology for precise measurement, with thresholds defined for optimal, borderline, and increased risk categories. Results can help clinicians personalize prevention and management strategies — including more aggressive risk factor modification — by identifying patients who may benefit from targeted therapeutic approaches. This test is offered on a clinical basis through Boston Heart Diagnostics under license from Kleanthi Diagnostics.

See Boston Heart Diagnostics specimen prep sheet for info on prepping specimens for testing.

Pharmaceutical Research Tests

Medpace licenses our OxPL-apoB and OxPL-apo(a) methods to support advanced research and clinical trial applications focused on oxidized phospholipid biology. Through its central laboratory services, Medpace offers highly validated assays that quantify oxidized phospholipids on apoB-containing lipoproteins and lipoprotein(a) [Lp(a)]—key drivers of vascular inflammation and atherosclerotic cardiovascular disease. These assays are derived from the original gold-standard methods developed by leaders in the field and use the well-characterized E06 monoclonal antibody to ensure specificity for oxidized (but not native) phospholipids. As sensitive pharmacodynamic and mechanistic biomarkers, OxPL-apoB and OxPL-apo(a) are widely used in cardiovascular research, particularly for evaluating Lp(a)-lowering therapies, residual inflammatory risk, and oxidative stress pathways in drug development. Through this licensing partnership, Medpace enables sponsors to incorporate rigorously validated OxPL biomarkers into GCP-aligned clinical trials and translational research programs.

Please view our collaborative white paper for more info.

Reagent Sales

We supply high-quality research reagents through Megaron and Millipore that support work with oxidized phospholipids and related biomarkers.

One key example is the anti-oxidized phospholipid antibody (clone EO6), a purified monoclonal antibody that specifically binds oxidized phospholipids on lipoproteins and other oxidatively modified proteins — a critical tool in cardiovascular and oxidative stress research and widely used in ELISA, immunohistochemistry (IHC), radioimmunoassay (RIA), and Western blot applications.

These reagents are intended for research use only and are popular choices for investigators studying oxidative modifications of lipids and proteins, developing assays, or probing biological mechanisms in vitro. By offering these Millipore reagents alongside our licensed diagnostic assays, we support both clinical and research communities in advancing lipid oxidation science and cardiovascular biomarker development.

Please contact us for more details on purchasing reagents and we can direct you to the right place.